Senores Pharma Strengthens US Footprint by Forming a New Subsidiary and a Favourable USFDA Verdict
Ahmedabad, 06th November, 2025: Senores Pharmaceuticals Limited (“Company”) recently reported two major developments to solidify its position as a strong regulatory company in the US and strengthen its growth strategy.
The Company’s wholly owned subsidiary, Senores Pharmaceuticals Inc. (SPI), acquired a 51% stake in Zoraya Pharmaceuticals LLC, Delaware, USA through a subscription of membership interest. With this move, Zoraya has become a step-down subsidiary of the Company, bolstering its operations and product development strengths in the US.
In a separate announcement, its material subsidiary, Havix Group Inc. D/B/A Aavis Pharmaceuticals (“Havix”), based in Georgia, USA, received an Establishment Inspection Report (EIR) from the US Food and Drug Administration after a successful inspection in July 2025. The inspection concluded with three minor observations, all of which have been resolved to the satisfaction of the USFDA, marking the closure of the inspection.
Commenting on this, Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited, said, “This dual milestone reflects our unwavering focus on quality, compliance, and global expansion. The Zoraya collaboration represents an important move forward in strengthening our US operations as well as expanding the specialty-portfolio. The positive EIR outcome reaffirms Havix’s robust manufacturing standards and underscores the company’s consistent ability to meet stringent global regulatory expectations and deliver products of the highest quality.”
